Immunovant (IMVT) Stock Forecast & Price Target

Compare

851 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMVT Analyst Ratings

Strong Buy

10 Buy

3 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Immunovant

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMVT Stock 12 Month Forecast

Average Price Target

$37.83

▲(155.26% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $37.83 with a high forecast of $57.00 and a low forecast of $18.00. The average price target represents a 155.26% change from the last price of $14.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","25":"$25","36":"$36","47":"$47","58":"$58"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,25,36,47,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.71,18.886153846153846,22.06230769230769,25.23846153846154,28.414615384615384,31.59076923076923,34.76692307692308,37.94307692307692,41.11923076923077,44.29538461538461,47.47153846153846,50.6476923076923,53.823846153846155,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.71,17.411538461538463,19.113076923076925,20.814615384615387,22.51615384615385,24.21769230769231,25.91923076923077,27.62076923076923,29.322307692307692,31.023846153846154,32.72538461538461,34.426923076923075,36.128461538461536,{"y":37.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.71,15.886153846153848,16.062307692307694,16.23846153846154,16.414615384615384,16.590769230769233,16.766923076923078,16.943076923076923,17.119230769230768,17.295384615384616,17.47153846153846,17.647692307692306,17.823846153846155,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.87,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$57.00

Average Price Target$37.83

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Smith

Leerink Partners

$52

Buy

250.88%

Upside

Reiterated

08/12/25

Immunovant's Promising Pipeline and Strategic Focus Justify Buy RatingWe look forward to the 6-month remission results, where we believe encouraging data would build on these initial bato results and provide positive readthrough to ‘1402. IMVT recently initiated a second potentially registrational trial in GD, and topline readouts from potentially registrational studies are anticipated in 2027. Beyond GD, other trials for ‘1402 are ongoing with open-label data in D2T RA and topline results from the POC study in CLE expected in 2026, while topline readouts from and MG remain anticipated in 2027. Lastly, Phase 3 results for bato in thyroid eye disease (TED) remain on track for 2H25, where mgmt. believes the data will provide more insight into the potential role of FcRn inhibition in GD. IMVT expects to make a decision on future TED development following the readout.

Derek Archila

Wells Fargo

$45

Buy

203.64%

Upside

Reiterated

08/12/25

Immunovant's Promising Pipeline and Strong Financial Position Signal a Buy Rating

Douglas Tsao

H.C. Wainwright

$35

Buy

136.17%

Upside

Reiterated

08/12/25

Immunovant's Promising Advances in Graves' Disease Treatment Drive Buy Rating

Samantha Semenkow

Citi

$58→$57

Buy

284.62%

Upside

Reiterated

08/12/25

Immunovant's IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs

Brian Cheng

J.P. Morgan

$40→$37

Buy

149.66%

Upside

Reiterated

08/12/25

Immunovant price target lowered to $37 from $40 at JPMorganImmunovant price target lowered to $37 from $40 at JPMorgan

Sam Slutsky

LifeSci Capital

$50

Buy

237.38%

Upside

Reiterated

08/11/25

Immunovant's Strategic Advancements and Clinical Progress Justify Buy Rating

Eddie Hickman

Guggenheim

$44

Buy

196.90%

Upside

Reiterated

08/11/25

Immunovant (IMVT) Receives a Buy from Guggenheim

Jason Gerberry

Bank of America Securities

$33→$30

Buy

102.43%

Upside

Reiterated

08/11/25

Bank of America Securities Keeps Their Buy Rating on Immunovant (IMVT)

Alex Thompson CFA

Stifel Nicolaus

$61→$50

Buy

237.38%

Upside

Reiterated

08/11/25

Stifel Nicolaus Sticks to Their Buy Rating for Immunovant (IMVT)Stifel analyst Alex Thompson lowered the price target on Immunovant (NASDAQ: IMVT) to $50.00 (from $61.00) while maintaining a Buy rating.

Ashwani Verma

UBS

$17→$18

Hold

21.46%

Upside

Reiterated

07/29/25

Immunovant price target raised to $18 from $17 at UBSImmunovant price target raised to $18 from $17 at UBS

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

07/25/25

Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald

Corinne Johnson

Goldman Sachs

$18

Hold

21.46%

Upside

Initiated

07/10/25

Goldman Sachs Resumes Coverage with a Hold Rating on Immunovant (IMVT)

Dennis Ding

Jefferies

$20→$18

Hold

21.46%

Upside

Reiterated

05/29/25

Jefferies Keeps Their Hold Rating on Immunovant (IMVT)

Leland Gershell

Oppenheimer

$54

Buy

264.37%

Upside

Reiterated

03/20/25

Oppenheimer reiterates Outperform Rating on Immunovant (IMVT)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $54.00 price target on Immunovant (NASDAQ: IMVT).

Yasmeen Rahimi

Piper Sandler

$57

Buy

284.62%

Upside

Reiterated

02/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunovant (NASDAQ: IMVT), Summit Therapeutics (NASDAQ: SMMT) and Outset Medical (NASDAQ: OM)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Smith

Leerink Partners

$52

Buy

250.88%

Upside

Reiterated

08/12/25

Derek Archila

Wells Fargo

$45

Buy

203.64%

Upside

Reiterated

08/12/25

Immunovant's Promising Pipeline and Strong Financial Position Signal a Buy Rating

Douglas Tsao

H.C. Wainwright

$35

Buy

136.17%

Upside

Reiterated

08/12/25

Immunovant's Promising Advances in Graves' Disease Treatment Drive Buy Rating

Samantha Semenkow

Citi

$58→$57

Buy

284.62%

Upside

Reiterated

08/12/25

Immunovant's IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs

Brian Cheng

J.P. Morgan

$40→$37

Buy

149.66%

Upside

Reiterated

08/12/25

Immunovant price target lowered to $37 from $40 at JPMorganImmunovant price target lowered to $37 from $40 at JPMorgan

Sam Slutsky

LifeSci Capital

$50

Buy

237.38%

Upside

Reiterated

08/11/25

Immunovant's Strategic Advancements and Clinical Progress Justify Buy Rating

Eddie Hickman

Guggenheim

$44

Buy

196.90%

Upside

Reiterated

08/11/25

Immunovant (IMVT) Receives a Buy from Guggenheim

Jason Gerberry

Bank of America Securities

$33→$30

Buy

102.43%

Upside

Reiterated

08/11/25

Bank of America Securities Keeps Their Buy Rating on Immunovant (IMVT)

Alex Thompson CFA

Stifel Nicolaus

$61→$50

Buy

237.38%

Upside

Reiterated

08/11/25

Ashwani Verma

UBS

$17→$18

Hold

21.46%

Upside

Reiterated

07/29/25

Immunovant price target raised to $18 from $17 at UBSImmunovant price target raised to $18 from $17 at UBS

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

07/25/25

Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald

Corinne Johnson

Goldman Sachs

$18

Hold

21.46%

Upside

Initiated

07/10/25

Goldman Sachs Resumes Coverage with a Hold Rating on Immunovant (IMVT)

Dennis Ding

Jefferies

$20→$18

Hold

21.46%

Upside

Reiterated

05/29/25

Jefferies Keeps Their Hold Rating on Immunovant (IMVT)

Leland Gershell

Oppenheimer

$54

Buy

264.37%

Upside

Reiterated

03/20/25

Oppenheimer reiterates Outperform Rating on Immunovant (IMVT)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $54.00 price target on Immunovant (NASDAQ: IMVT).

Yasmeen Rahimi

Piper Sandler

$57

Buy

284.62%

Upside

Reiterated

02/25/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunovant (NASDAQ: IMVT), Summit Therapeutics (NASDAQ: SMMT) and Outset Medical (NASDAQ: OM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunovant

1 Month

xxx

Success Rate

22/39 ratings generated profit

Average Return

+3.87%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.41% of your transactions generating a profit, with an average return of +3.87% per trade.

3 Months

xxx

Success Rate

10/19 ratings generated profit

Average Return

+14.38%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +14.38% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

7/19 ratings generated profit

Average Return

+23.73%

reiterated a buy rating 11 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 36.84% of your transactions generating a profit, with an average return of +23.73% per trade.

2 Years

xxx

Success Rate

5/18 ratings generated profit

Average Return

+38.19%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 27.78% of your transactions generating a profit, with an average return of +38.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMVT Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMVT has received 12 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMVT average Analyst price target in the past 3 months is 37.83.

Each month's total comprises the sum of three months' worth of ratings.

IMVT Financial Forecast

IMVT Earnings Forecast

Next quarter’s earnings estimate for IMVT is -$0.71 with a range of -$0.80 to -$0.59. The previous quarter’s EPS was -$0.71. IMVT beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.05% of the time in the same period. In the last calendar year IMVT has Outperformed its overall industry.

No data currently available

IMVT Sales Forecast

Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year IMVT has Preformed in-line its overall industry.

IMVT Stock Forecast FAQ

What is IMVT’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunovant’s 12-month average price target is 37.83.

What is IMVT’s upside potential, based on the analysts’ average price target?

Immunovant has 155.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMVT a Buy, Sell or Hold?

Immunovant has a consensus rating of Strong Buy which is based on 10 buy ratings, 3 hold ratings and 0 sell ratings.

What is Immunovant’s price target?

The average price target for Immunovant is 37.83. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $57.00 ,the lowest forecast is $18.00. The average price target represents 155.26% Increase from the current price of $14.82.

What do analysts say about Immunovant?

Immunovant’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of IMVT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Immunovant (IMVT) Stock Forecast & Price Target

IMVT Analyst Ratings

IMVT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunovant

IMVT Analyst Recommendation Trends

IMVT Financial Forecast

IMVT Earnings Forecast

IMVT Sales Forecast

IMVT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts